Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Gross Profit: 2013-2024

Historic Gross Profit for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $14.7 million.

  • ImmunityBio's Gross Profit rose 422.17% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.2 million, marking a year-over-year increase of 1020.89%. This contributed to the annual value of $14.7 million for FY2024, which is 2270.58% up from last year.
  • As of FY2024, ImmunityBio's Gross Profit stood at $14.7 million, which was up 2,270.58% from $622,000 recorded in FY2023.
  • In the past 5 years, ImmunityBio's Gross Profit registered a high of $14.7 million during FY2024, and its lowest value of $240,000 during FY2022.
  • Its 3-year average for Gross Profit is $5.2 million, with a median of $622,000 in 2023.
  • As far as peak fluctuations go, ImmunityBio's Gross Profit crashed by 74.30% in 2022, and later spiked by 2,270.58% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Gross Profit stood at $605,000 in 2020, then skyrocketed by 54.38% to $934,000 in 2021, then slumped by 74.30% to $240,000 in 2022, then soared by 159.17% to $622,000 in 2023, then skyrocketed by 2,270.58% to $14.7 million in 2024.